Search all trials

Find therapies in clinical trials near you

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

K-ras gene mutation+1

Recruiting

Registered drugNo placebo

A study of pembrolizumab, cetuximab, and MK-1084 for patients with advanced or metastatic non-small cell lung cancer with KRAS G12C mutations

Registered drugNo placebo

Finland

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

K-ras gene mutation+1

Recruiting

Registered drugNo placebo

Evaluation of Safety, Pharmacokinetics, and Efficacy of RO7782493 and Panitumumab in Advanced Solid Tumors with KRAS G12D Mutation

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Panitumumab

Contact Research Centre

K-ras gene mutation+2

Recruiting

Registered drugNo placebo

Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Budesonide

Contact Research Centre

K-ras gene mutation+1

Recruiting

Registered drugNo placebo

Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer

Registered drugNo placebo

Finland

Participants:18–64 years · 65+ years
Substances:Bevacizumab

Contact Research Centre

K-ras gene mutation+2

Not recruiting

Registered drugNo placebo

Study Comparing Divarasib, Sotorasib, and Adagrasib for Patients with Advanced or Metastatic KRAS G12C-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years

Contact Research Centre

K-ras gene mutation+3

Not recruiting

InvestigationalNo placebo

Study of JDQ443, TNO155, and Tislelizumab for Patients with Advanced Solid Tumors with KRAS G12C Mutation

InvestigationalNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Batoprotafib

Contact Research Centre

K-ras gene mutation+2

Not recruiting

Registered drugNo placebo

Study on Sotorasib for Patients with Advanced KRAS G12C-Mutated Non-Small Cell Lung Cancer and Comorbidities

Registered drugNo placebo

Denmark

Participants:18–64 years · 65+ years
Substances:Sotorasib

Contact Research Centre

K-ras gene mutation+1

Not recruiting

InvestigationalNo placebo

Study of adagrasib in elderly patients (70 years or older) or patients with poor performance status who have KRAS G12C mutation-positive non-small cell lung cancer

InvestigationalNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Adagrasib

Contact Research Centre

K-ras gene mutation+1

Not recruiting

Registered drugNo placebo

Study of Sotorasib Treatment in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation Who Have Previously Received Treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Sotorasib

Contact Research Centre

K-ras gene mutation+3

Not recruiting

Registered drugNo placebo

Study of JDQ443 and Ribociclib in Combination for Adult Patients with Advanced Solid Tumors with KRAS G12C Mutation

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Cetuximab

Contact Research Centre

K-ras gene mutation

Not recruiting

Registered drugNo placebo

Study of BMS-986466 with Adagrasib and Cetuximab for Patients with KRAS G12C-mutant Advanced Solid Tumors

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Adagrasib

Contact Research Centre

Find therapies in clinical trials near you

11 trials match your criteria

K-ras gene mutation+1

A study of pembrolizumab, cetuximab, and MK-1084 for patients with advanced or metastatic non-small cell lung cancer with KRAS G12C mutations

K-ras gene mutation+1

Evaluation of Safety, Pharmacokinetics, and Efficacy of RO7782493 and Panitumumab in Advanced Solid Tumors with KRAS G12D Mutation

K-ras gene mutation+2

Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer

K-ras gene mutation+1

Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer

K-ras gene mutation+2

Study Comparing Divarasib, Sotorasib, and Adagrasib for Patients with Advanced or Metastatic KRAS G12C-Positive Non-Small Cell Lung Cancer

K-ras gene mutation+3

Study of JDQ443, TNO155, and Tislelizumab for Patients with Advanced Solid Tumors with KRAS G12C Mutation

K-ras gene mutation+2

Study on Sotorasib for Patients with Advanced KRAS G12C-Mutated Non-Small Cell Lung Cancer and Comorbidities

K-ras gene mutation+1

Study of adagrasib in elderly patients (70 years or older) or patients with poor performance status who have KRAS G12C mutation-positive non-small cell lung cancer

K-ras gene mutation+1

Study of Sotorasib Treatment in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation Who Have Previously Received Treatment

K-ras gene mutation+3

Study of JDQ443 and Ribociclib in Combination for Adult Patients with Advanced Solid Tumors with KRAS G12C Mutation

K-ras gene mutation

Study of BMS-986466 with Adagrasib and Cetuximab for Patients with KRAS G12C-mutant Advanced Solid Tumors

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.